HIGHLIGHTS
- who: Zhujun Liu from the Medical University Cancer Institute and Hospital, Research and Development Department, Jiangsu Chia-Tai Tian Qing Pharmaceutical Co, Ltd, Nanjing, China have published the paper: Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab, in the Journal: (JOURNAL)
- what: The aim of this study was to confirm the effect of bevacizumab on TGFb signaling, to elucidate downstream signaling molecules, and to determine whether anlotinib can reverse resistance to bevacizumab. The study has some limitations in that the molecular mechanisms by which bevacizumab and anlotinib affect the expression or activity of TGFb have not . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.